Abstract: A composition comprising a heat transfer portion and a lubricating portion, wherein the lubricating portion comprises one or more compounds according to formula (I): wherein W is independently selected from the group consisting of H, F, Cl, Br and I; Y is independently selected from the group consisting of F, Cl, Br and I; Z is independently selected from the group consisting of H, OH, (CW2)PCW3, CY3, OCW3, O(CW2)pCW3, OCW((CY2)mCY3)CWCW2, polyalkylene glycol and polyolester; n is an integer from 2 to 250; m is an integer from 0 to 3; and p is an integer from 0 to 9.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one indacaterol compound selected from indacaterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: The present invention relates to compounds according to formula (Ia) or formula (Ib); wherein each W is independently selected from the group consisting of H, F, Cl, Br, I and (CY2)mCY3; each Y is independently selected from the group consisting of F, Cl, Br and I; each Z is independently selected from the group consisting of H, OH, (CW2)pCW3, CY3, OCW3, O(CW2)pCW3, OCW((CY2)mCY3)CWCW2, (CW2)pOH, polyalkylene glycol and polyolester; n is an integer from 2 to 49; m is an integer from 0 to 3; p is an integer from 0 to 9; the molecular weight average (MW) is ?5500; and the polydispersity index is ?1.45; compositions comprising these compounds and methods for their production.

Abstract: The present invention provides a process for preparing 3,3,3-trifluoropropene (1243zf), the process comprising: (a) fluorinating CCl3CH2CH2Cl (250fb) to produce a reaction product comprising CF3CH2CH2Cl (253fb) in the liquid phase in a first reactor, using HF as the fluorinating agent; and (b) (i) dehydrohalogenating 253fb to produce 1243zf in the vapour phase in the present of a catalyst in a second reactor; or (b)(ii) dehydrohalogenating 253fb to produce 1243zf in a second reactor, wherein the reaction product comprising 253fb produced in step (a) has subjected to one or more purification steps before step (b). The present invention also provides an azeotropic or near-azeotropic composition comprising HF and 253fb.

Abstract: A composition comprising a heat transfer portion and a lubricating portion, wherein the lubricating portion comprises one or more compounds according to formula (I) of the present disclosure, wherein W is H; Y is independently selected from the group consisting of F, Cl, Br and I; Z is independently selected from the group consisting of H, OH, (CW2)PCW3, CY3, OCW3, 0(CW2)pCW3, OCW((CY2)mCY3)CWCW2, polyalkylene glycol and polyolester; n is an integer from 2 to 250; m is an integer from 0 to 3; and p is an integer from 0 to 9.

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

Abstract: The invention provides a composition comprising 1,1-difluoroethene (R-1132a), difluoromethane (R-32), 2,3,3,3-tetrafluoropropene (R-1234yf), optionally carbon dioxide (CO2, R-744), and, optionally, 1,1,2-trifluoroethene (R-1123).

Abstract: The invention provides a composition comprising 1,1-difluoroethene (R-1132a), difluoromethane (R-32), 2,3,3,3-tetrafluoropropene (R-1234yf), optionally carbon dioxide (CO2, R-744), and, optionally, 1,1,2-trifluoroethene (R-1123).

Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).

Abstract: The present invention provides a process for preparing 1,1,1,2,2-pentafluoropropane (245cb), the process comprising gas phase catalytic dehydrochlorination of a composition comprising 1,1,1-trifluoro-2,3-dichloropropane (243db) to produce an intermediate composition comprising 3,3,3-trifluoro-2-chloro-prop-1-ene (CF3CCl?CH2, 1233xf), hydrogen chloride (HCl) and, optionally, air; and gas phase catalytic fluorination with hydrogen fluoride (HF) of the intermediate composition to produce a reactor product composition comprising 245cb, HF, HCl and air; wherein the process is carried out with a co-feed of air.

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, budesonide, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

Abstract: The invention provides a composition comprising 1,1-difluoroethene (R-1132a), difluoromethane (R-32), 2,3,3,3-tetra-fluoropropene (R-1234yf), optionally carbon dioxide (CO2, R-744), and, optionally, 1,1,2-trifluoroethene (R-1123).

Abstract: A pharmaceutical composition is described. The composition may include: (i) a drug component including at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component including 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition comprises; (i) a drug component comprising salbutamol; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: The present disclosure provides compounds of formula (I), and preparation method thereof, wherein W is independently selected from the group consisting of H, F, Cl, Br and I; X is independently selected from the group consisting of H, F, Cl, Br, I, CW3 and OR on the basis that at least one X is OR; R is independently selected from the group consisting of C(O)CH2)m(CF2)nY and CW2C(CW2OC(O)(CH2)m(CF2)nY)3; m is an integer from 0 to 2; 15 n is an integer from 2 to 8; Y is C(Z)3; and Z is independently selected from the group consisting of H, F, Cl, Br and I. Such compounds may be utilised as lubricants, for example in heat transfer compositions.

Abstract: The present invention provides a process for preparing 3,3,3-trifluoropropene (1243zf), the process comprising: (a) fluorinating CCI3CH2CH2CI (250fb) to produce a reaction product comprising CF3CH2CH2CI (253fb) in the liquid phase in a first reactor, using HF as the fluorinating agent; and (b)(i) dehydrohalogenating 253fb to produce 1243zf in the vapour phase in the presence of a catalyst in a second reactor; or (b)(ii) dehydrohalogenating 253fb to produce 1243zf in a second reactor, wherein the reaction product comprising 253fb produced in step (a) has subjected to one or more purification steps before step (b). The present invention also provides an azeotropic or near-azeotropic composition comprising HF and 253fb.

Abstract: A process for treating a composition comprising one or more desired (hydro)fluoroolefins and one or more undesired halogenated ethanes, halogenated methanes or mixtures thereof so as to reduce the concentration of at least one undesired halogenated ethane or halogenated methane, the process comprising contacting the composition with an adsorbent comprising pores having openings which have a size across their largest dimension of about 6 ? or less.